IVISense™ Cat K 680 FAST NIR fluorescent probe enables monitoring and quantifying cathepsin K (Cat K) activity.
Cat K is a lysosomal cysteine protease expressed in osteoclasts, chondrocytes, and synovial fibroblasts and is involved in bone resorption and collagen degradation. Women with osteoporosis, breast cancer and bone metastases are reported to have high levels of Cat K. The high expression levels of Cat K is a good marker for not only better understanding bone modeling and remodeling, but evaluating inhibitors of Cat K for potential therapeutics.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Cat K 680 FAST is a Cathepsin K (Cat K) activatable fluorescent agent that is optically silent upon injection and produces fluorescent signal after cleavage by disease related Cathepsin K. Cat K is highly expressed in osteoclasts, suggesting a specialized role in bone resorption.
Cat K is found extracellularly along the bone and cartilage and intracellularly in lysozomes of osteoclasts attached to the bone. In addition to expression by osteoclasts, Cat K is also expressed by a broad range of other cell types including ovarian cells, colonic tissue, alveolar and bronchial epithelial cells, synovial fibroblasts, breast cancer cells, macrophages.
Cat K 680 FAST fluorescent probe is a member of a family of activatable imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology), that confers an improved pharmacokinetic profile with earlier imaging time points. This architecture offers higher target specific signal with reduced background while also reducing the optimal imaging time after injection.
|Fluorescent Agent Type||Activatable|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Atherosclerosis, Arthritis|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Current means of measuring disease in preclinical models of atherosclerosis include ex vivo assessment of disease tissues post-mortem and non-invasive imaging primarily of structural and anatomic features of lesions, in vivo. A non-invasive, quantitative means of imaging known biologic profiles asso ...
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And ...
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best p ...
The goal of in vivo fluorescence molecular imaging is to enable non-invasive visualization and quantification of cellular and biological functioning to better understand and characterize disease processes and treatment effects earlier within the context of a biological system.
This s ...
Cat K 680 FAST is a cathepsin K activatable agent that is optically silent upon injection and produces fluorescent signal after being cleaved by disease-related cathepsin K. Cathepsin K is highly expressed in osteoclasts, suggesting a specialized role in bone resorption, and also in synovial fibrobl ...
Imaging of Cathepsin K activity in rodent models of bone turnover and soft tissue calcification
Cat K 680 FAST activatable fluorescent imaging agent protocol
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick ...